# Pfizer Inc.

## Overview

Pfizer Inc. (PFE)

- **Exchange:** NYSE
- **Current Share Price:** $26.70
- **Change:** +$0.44 (1.68%)

## Notable Price Movement

### After Hours
* **Date:** Apr 30  
* **Price:** $26.70 (1.68% at Close)  
* **After Hours Price:** $26.68 (0.07% After Hours)

Pfizer rose nearly 2% on April 30, buoyed by a confluence of positive catalysts. Earlier in the week, the company announced patent settlements for its ATTR-CM drug Vyndamax with three generic manufacturers, extending U.S. exclusivity to mid-2031 and stabilizing revenue expectations from 2028 onward. Additionally, Pfizer reported positive Phase 3 results for ELREXFIO in relapsed/refractory multiple myeloma, showing statistically significant improvement in progression-free survival versus standard of care. These developments come ahead of Pfizer's May 5 earnings report, with analyst consensus holding a Hold rating and an average price target of $29.42, while some valuation models suggest meaningful upside from current levels.

### Price Change History
| Date       | Closing Price | Change   |
|------------|---------------|----------|
| Apr 29    | $26.27        | -0.79%   |
| Apr 28    | $26.48        | -1.18%   |
| Apr 27    | $26.81        | -0.70%   |
| Apr 24    | $26.98        | +1.16%   |
| Apr 23    | $26.66        | -0.53%   |
| Apr 22    | $26.78        | -1.94%   |
| Apr 21    | $27.31        | -0.76%   |
| Apr 20    | $27.52        | +0.15%   |
| Apr 19    | $27.56        | +1.25%   |
| Apr 18    | $27.21        | +0.07%   |
| Apr 17    | $27.32        | +1.49%   |
| Apr 16    | $27.13        | +0.77%   |
| Apr 15    | $27.19        | +0.30%   |

## Analyst Consensus  
**Consensus:** Hold  
- **Bearish:** 1  
- **Neutral:** 5  
- **Bullish:** 3  
- **Price Targets:** 
  - **Low:** $25  
  - **Current:** $26.70  
  - **Average:** $29  
  - **High:** $36

## Key Issues  
### Valuation  
- **Bullish View:** Pfizers discounted cash flow analysis suggests shares are approximately 59% below estimated intrinsic value of ~$64.92.  
- **Bearish View:** GuruFocus's GF Value model indicates Pfizer's intrinsic value at $25.53, suggesting current stock prices might be overvalued.

### Additional Information  
- **Symbol:** PFE  
- **IPO Date:** May 31, 1972  
- **CEO:** Albert Bourla  
- **Fulltime Employees:** 81K  
- **Country:** United States  
- **Sector:** Healthcare  
- **Industry:** Drug Manufacturers - General